title: [(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease.
abstract: OBJECTIVE
  Visualization of the spatial distribution of neurofibrillary tangles would help in the diagnosis, prevention and treatment of dementia. The purpose of the study was to evaluate the clinical utility of [(18)F]THK-5117 as a highly selective tau imaging radiotracer.
  
  
  METHODS
  We initially evaluated in vitro binding of [(3)H]THK-5117 in post-mortem brain tissues from patients with Alzheimer's disease (AD). In clinical PET studies, [(18)F]THK-5117 retention in eight patients with AD was compared with that in six healthy elderly controls. Ten subjects underwent an additional [(11)C]PiB PET scan within 2 weeks.
  
  
  RESULTS
  In post-mortem brain samples, THK-5117 bound selectively to neurofibrillary deposits, which differed from the binding target of PiB. In clinical PET studies, [(18)F]THK-5117 binding in the temporal lobe clearly distinguished patients with AD from healthy elderly subjects. Compared with [(11)C]PiB, [(18)F]THK-5117 retention was higher in the medial temporal cortex.
  
  
  CONCLUSIONS
  These findings suggest that [(18)F]THK-5117 provides regional information on neurofibrillary pathology in living subjects.
authors: Division of Neuro-imaging, Institute of Development, Aging and Cancer, Tohoku University, Sendai, 980-8575, Japan.
authors: Ryuichi
authors: R
authors: Harada
authors: Nobuyuki
authors: N
authors: Okamura
authors: Shozo
authors: S
authors: Furumoto
authors: Katsutoshi
authors: K
authors: Furukawa
authors: Aiko
authors: A
authors: Ishiki
authors: Naoki
authors: N
authors: Tomita
authors: Kotaro
authors: K
authors: Hiraoka
authors: Shoichi
authors: S
authors: Watanuki
authors: Miho
authors: M
authors: Shidahara
authors: Masayasu
authors: M
authors: Miyake
authors: Yoichi
authors: Y
authors: Ishikawa
authors: Rin
authors: R
authors: Matsuda
authors: Akie
authors: A
authors: Inami
authors: Takeo
authors: T
authors: Yoshikawa
authors: Tetsuro
authors: T
authors: Tago
authors: Yoshihito
authors: Y
authors: Funaki
authors: Ren
authors: R
authors: Iwata
authors: Manabu
authors: M
authors: Tashiro
authors: Kazuhiko
authors: K
authors: Yanai
authors: Hiroyuki
authors: H
authors: Arai
authors: Yukitsuka
authors: Y
authors: Kudo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000473:pathology; D000814:Aniline Compounds / Q000493:pharmacokinetics* / Q000494:pharmacology; D052160:Benzothiazoles; D016022:Case-Control Studies; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D009454:Neurofibrils / Q000000981:diagnostic imaging* / Q000473:pathology; D049268:Positron-Emission Tomography; D011804:Quinolines / Q000493:pharmacokinetics* / Q000494:pharmacology; D019275:Radiopharmaceuticals; D013844:Thiazoles
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; C000604726:6-((3-fluoro-2-hydroxy)propoxy)-2-(4-methylaminophenyl)quinoline; D000814:Aniline Compounds; D052160:Benzothiazoles; D011804:Quinolines; D019275:Radiopharmaceuticals; C000590971:THK5105; D013844:Thiazoles